ArticleBMC public health2014
Preference, acceptability and implications of the rapid hepatitis C screening test among high-risk young people who inject drugs.
Article in BMC public health, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis.Substance abuse treatment, prevention, and policy · 2020Pooled it
- Investigating hepatitis C screening among people receiving opioid agonist treatment: A retrospective audit study.Journal of infection prevention · 2024Article
- Rapid point-of-care testing for hepatitis C - assessment of feasibility, knowledge of participants and outcomes.Gastroenterology and hepatology from bed to bench · 2024Article
- Combined COVID-19 vaccination and hepatitis C virus screening intervention in marginalised populations in Spain.Communications medicine · 2023Article
- Preferences for an HIV Self-Testing Program Among Women who Engage in sex Work and use Drugs in Kazakhstan, Central Asia.Research on social work practice · 2023Article
- Design and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistence.Contemporary clinical trials communications · 2021Article
- Rapid point-of-care (POC) testing for Hepatitis C antibodies in a very high prevalence setting: persons injecting drugs in Tallinn, Estonia.Harm reduction journal · 2021Article
- High hepatitis C virus seropositivity, viremia, and associated risk factors among trans women living in San Francisco, California.PloS one · 2021Article
- Acceptability of on-site rapid HIV/HBV/HCV testing and HBV vaccination among three at-risk populations in distinct community-healthcare outreach centres: the ANRS-SHS 154 CUBE study.BMC infectious diseases · 2020Article
- Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trial.Health science reports · 2020Article
- A population-based screening for hepatitis C antibodies and active infection using a point-of-care test in a low prevalence area.PloS one · 2020Article
- European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift.World journal of hepatology · 2018Article
- Management of acute HCV infection in the era of direct-acting antiviral therapy.Nature reviews. Gastroenterology & hepatology · 2018Review
- Acceptability of Rapid Point-of-Care Hepatitis C Tests Among People Who Inject Drugs and Utilize Syringe-Exchange Programs.Open forum infectious diseases · 2016Article
- Simultaneous Human Immunodeficiency Virus-Hepatitis B-Hepatitis C Point-of-Care Tests Improve Outcomes in Linkage-to-Care: Results of a Randomized Control Trial in Persons Without Healthcare Coverage.Open forum infectious diseases · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundPeople who inject drugs (PWID) are at highest risk for hepatitis C virus (HCV) infection, yet many remain unaware of their infection status. New anti-HCV rapid testing has high potential to impact this.
methodsYoung adult (<30 years) active PWID were offered either the rapid OraQuick® or standard anti-HCV test involving phlebotomy, then asked to complete a short questionnaire about testing perceptions and preferences. Sample characteristics, service utilization, and injection risk exposures are assessed with the HCV testing choice as the outcome, testing preferences, and reasons for preference.
resultsOf 129 participants: 82.9% (n = 107) chose the rapid test. There were no significant differences between those who chose rapid vs. standard testing. A majority (60.2%) chose the rapid test for quick results; most (60.9%) felt the rapid test was accurate, and less painful (53.3%) than the tests involving venipuncture.
conclusionsOraQuick® anti-HCV rapid test was widely accepted among young PWID. Our results substantiate the valuable potential of anti-HCV rapid testing for HCV screening in this high risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.